CONGENITAL ADRENAL HYPERPLASIA
Clinical trials for CONGENITAL ADRENAL HYPERPLASIA explained in plain language.
Never miss a new study
Get alerted when new CONGENITAL ADRENAL HYPERPLASIA trials appear
Sign up with your email to follow new studies for CONGENITAL ADRENAL HYPERPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with rare hormone disorder: drug may cut steroid dependence
Disease control Recruiting nowThis study tests a new drug called atumelnant in children aged 1 to 17 with classic congenital adrenal hyperplasia, a genetic condition that disrupts hormone production. The goal is to see if the drug can safely control hormone levels and reduce the need for daily steroids. About…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE2, PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 08:47 UTC
-
New hope for CAH patients: Long-Term drug trial launches
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of an experimental drug called atumelnant (CRN04894) in 150 adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that affects hormone production. Participants must have completed a previous Crinetics…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 08:39 UTC
-
New Once-Daily pill could simplify CAH treatment
Disease control Recruiting nowThis study compares a new once-daily dual-release hydrocortisone to standard glucocorticoid therapy in 150 adults with congenital adrenal hyperplasia. The goal is to see if the new pill improves cholesterol, blood sugar, weight, blood pressure, and quality of life. Participants m…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE4 • Sponsor: Federico II University • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
New hope for babies with rare hormone disorder?
Disease control Recruiting nowThis study is testing an experimental drug called crinecerfont in 6 infants under 2 years old who have congenital adrenal hyperplasia (CAH), a condition where the body can't make certain hormones properly. The goal is to see how the drug moves through the body and if it is safe. …
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
New drug trial hopes to tame rare hormone disorder
Disease control Recruiting nowThis study tests a new medicine called Lu AG13909 in adults with congenital adrenal hyperplasia (CAH), a rare genetic condition that disrupts hormone production. The main goals are to see if the drug is safe, how it moves through the body, and how it affects hormone levels. About…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE1, PHASE2 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New hope for rare hormone disorder: atumelnant trial launches
Disease control Recruiting nowThis study tests an experimental drug called atumelnant in 150 adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. Participants will receive either atumelnant or a placebo to see if the drug can better control hormone le…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
New registry aims to shed light on rare diseases
Knowledge-focused Recruiting nowThis study is creating a large database to collect information about people with rare diseases like amyloidosis, sarcoidosis, and many others. Researchers will track patients' health, treatments, and outcomes over time. The goal is to better understand these conditions and improv…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Sponsor: Hospital Italiano de Buenos Aires • Aim: Knowledge-focused
Last updated May 26, 2026 08:29 UTC